La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Amryt Pharma Gestion

Gestion contrôle des critères 3/4

Le PDG Amryt Pharma's est Joe Wiley, nommé en Jan2015, a un mandat de 8.25 ans. La rémunération annuelle totale est $ 1.72M, composée du salaire de 43.4% et des bonus 56.6%, y compris les actions et options de la société. détient directement 1.1% des actions de la société, d'une valeur de $ 10.36M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 3.6 ans.

Informations clés

Joe Wiley

Directeur général

US$1.7m

Rémunération totale

Pourcentage du salaire du PDG	43.4%
Durée du mandat du directeur général	8.3yrs
Propriété du PDG	1.1%
Durée moyenne d'occupation des postes de direction	3.3yrs
Durée moyenne du mandat des membres du conseil d'administration	3.6yrs

Mises à jour récentes de la gestion

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

Analyse de la rémunération des PDG

Comment la rémunération de Joe Wiley a-t-elle évolué par rapport aux bénéfices de Amryt Pharma?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2022	n/a	n/a	-US$790k
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$3m
Dec 31 2021	US$2m	US$747k	US$1m
Sep 30 2021	n/a	n/a	-US$88m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$92m
Dec 31 2020	US$2m	US$727k	-US$105m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$92m
Mar 31 2020	n/a	n/a	-US$87m
Dec 31 2019	US$1m	US$588k	-US$63m

Rémunération vs marché: La rémunération totale de Joe ($USD 1.72M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 3.30M ).

Rémunération et revenus: La rémunération de Joe a augmenté alors que l'entreprise n'est pas rentable.

PDG

Joe Wiley (51 yo)

8.3yrs

Titularisation

US$1,720,000

Compensation

Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Joseph Wiley	CEO & Director	8.3yrs	US$1.72m	1.1% $ 10.4m
Rory Nealon	CFO, COO & Company Secretary	8.3yrs	US$939.00k	0.51% $ 4.8m
Elizabeth Jobes	Chief Compliance Officer	2.3yrs	pas de données	pas de données
John McEvoy	General Counsel	5.6yrs	pas de données	pas de données
Stephen Joyce	Head of Marketing & Head of APAC	4.3yrs	pas de données	pas de données
Julie Eastwood	Head of Human Resources	no data	pas de données	pas de données
Helen Phillips	Head of Medical Affairs	no data	pas de données	pas de données
Sheila Frame	President of Americas	2yrs	pas de données	pas de données
Tracy Cunningham	Chief Medical Officer	less than a year	pas de données	pas de données
Jordi Casals	President of EMEA Region	less than a year	pas de données	pas de données

3.3yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AMYT est considérée comme expérimentée (ancienneté moyenne 3.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Joseph Wiley	CEO & Director	7yrs	US$1.72m	1.1% $ 10.4m
Stephen Wills	Independent Non-Executive Director	3.6yrs	US$88.00k	0.023% $ 220.5k
Alain Munoz	Independent Non-Executive Director	3.6yrs	US$58.00k	0.0070% $ 66.1k
Patrick V. J. Vink	Independent Non-Executive Director	3.6yrs	US$60.00k	0.0078% $ 73.5k
Donald Stern	Independent Non-Executive Director	3.6yrs	US$80.00k	0% $ 0
Raymond Stafford	Independent Non-Executive Chairman of the Board	7yrs	US$88.00k	0.61% $ 5.8m
Roni Mamluk	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0
George Hampton	Independent Non-Executive Director	3.6yrs	US$65.00k	0.031% $ 294.0k
Raj Kannan	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0

3.6yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AMYT sont considérés comme expérimentés (ancienneté moyenne 3.6 ans).

Amryt Pharma Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Chiasma surges on merger agreement with Amryt

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Group's Lojuxta receives marketing approval in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen